Cantor Fitzgerald Increases Earnings Estimates for Humacyte

Humacyte, Inc. (NASDAQ:HUMA) – Analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for Humacyte in a research note issued to investors on Wednesday, January 15th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($1.40) for the year, up from their previous forecast of ($1.41). Cantor Fitzgerald currently has a “Overweight” rating and a $13.00 price target on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share.

A number of other research analysts also recently issued reports on HUMA. Benchmark upped their price target on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, December 23rd. D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of Humacyte in a research note on Monday, January 13th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. TD Cowen restated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price (up previously from $12.00) on shares of Humacyte in a research report on Friday, December 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $13.71.

Humacyte Trading Down 1.6 %

Shares of HUMA opened at $4.41 on Friday. The company has a market cap of $555.04 million, a price-to-earnings ratio of -3.29 and a beta of 1.32. The business’s fifty day simple moving average is $4.58 and its two-hundred day simple moving average is $5.66. Humacyte has a 12 month low of $2.53 and a 12 month high of $9.97.

Hedge Funds Weigh In On Humacyte

A number of hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC lifted its holdings in Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after purchasing an additional 524,600 shares in the last quarter. State Street Corp raised its position in shares of Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after buying an additional 1,895,529 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Humacyte in the third quarter worth $596,000. Thrivent Financial for Lutherans bought a new position in shares of Humacyte during the third quarter worth $712,000. Finally, Barclays PLC grew its stake in Humacyte by 177.6% during the third quarter. Barclays PLC now owns 236,742 shares of the company’s stock valued at $1,288,000 after acquiring an additional 151,458 shares in the last quarter. Institutional investors own 44.71% of the company’s stock.

Insider Transactions at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. This represents a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Laura E. Niklason sold 811,172 shares of Humacyte stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the transaction, the chief executive officer now owns 2,419,712 shares in the company, valued at approximately $10,743,521.28. This trade represents a 25.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock valued at $6,606,799 over the last quarter. 11.20% of the stock is currently owned by company insiders.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.